Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WAQAR SIDDIQUI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1699840314
CMS profile
212326
Location
SOUTH PLAINFIELD, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,352.08

118 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,292.09 117
Education $59.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WAQAR SIDDIQUI

NPI 1699840314 · CMS profile ID 212326

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SOUTH PLAINFIELD, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699840314?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WAQAR SIDDIQUI, NPI 1699840314, CMS profile ID 212326. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699840314?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WAQAR SIDDIQUI, NPI 1699840314, CMS profile ID 212326. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699840314?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WAQAR SIDDIQUI, NPI 1699840314, CMS profile ID 212326, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1699840314?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

118 matching records · $2,352.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 118 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 118.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $15.9712/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881725 CMS
ITI, Inc. $16.6712/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040701003 CMS
Teva Pharmaceuticals USA, Inc. $22.1712/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881715 CMS
AbbVie Inc. $22.1312/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001821 CMS
Alkermes, Inc. $23.1412/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022916749 CMS
Otsuka America Pharmaceutical, Inc. $22.8012/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818391 CMS
AbbVie Inc. $22.5212/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001817 CMS
Lundbeck LLC $22.1011/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032361407 CMS
Vanda Pharmaceuticals Inc. $27.2711/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051541883 CMS
AbbVie Inc. $22.1811/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001813 CMS
Otsuka America Pharmaceutical, Inc. $15.5011/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818381 CMS
Alkermes, Inc. $21.8411/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022916747 CMS
Teva Pharmaceuticals USA, Inc. $20.7411/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881713 CMS
Lundbeck LLC $20.3911/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032361395 CMS
Teva Pharmaceuticals USA, Inc. $10.4111/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881711 CMS
AbbVie Inc. $15.4511/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001810 CMS
Janssen Pharmaceuticals, Inc $18.6911/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988019437 CMS
Otsuka America Pharmaceutical, Inc. $25.7911/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818371 CMS
AbbVie Inc. $18.9011/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001806 CMS
Teva Pharmaceuticals USA, Inc. $12.1410/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881709 CMS
AbbVie Inc. $25.7210/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001803 CMS
Otsuka America Pharmaceutical, Inc. $16.9710/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818361 CMS
ITI, Inc. $17.0010/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040700997 CMS
Alkermes, Inc. $20.3710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022916745 CMS
Lundbeck LLC $16.1110/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032361385 CMS
Axsome Therapeutics, Inc. $23.1110/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056225733 CMS
AbbVie Inc. $21.4710/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001799 CMS
Vanda Pharmaceuticals Inc. $26.4109/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051541879 CMS
Indivior Inc. $29.0209/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034267287 CMS
Lundbeck LLC $10.3709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032361375 CMS
Insmed, Inc. $20.8109/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978799337 CMS
AbbVie Inc. $13.2109/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001795 CMS
ITI, Inc. $2.9609/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040700983 CMS
ITI, Inc. $19.4409/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040700991 CMS
Otsuka America Pharmaceutical, Inc. $15.9609/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818353 CMS
Teva Pharmaceuticals USA, Inc. $27.5208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881679 CMS
AbbVie Inc. $23.0708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001791 CMS
Lundbeck LLC $22.5208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032361359 CMS
Otsuka America Pharmaceutical, Inc. $19.6408/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818343 CMS
Indivior Inc. $29.6808/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034267279 CMS
AbbVie Inc. $21.1308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001787 CMS
Alkermes, Inc. $21.2408/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022916743 CMS
Teva Pharmaceuticals USA, Inc. $21.3808/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056881661 CMS
AbbVie Inc. $24.5408/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001783 CMS
Indivior Inc. $22.7307/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034267271 CMS
Otsuka America Pharmaceutical, Inc. $13.0607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014818333 CMS
AbbVie Inc. $17.9507/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001779 CMS
Alkermes, Inc. $20.7107/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022916741 CMS
Axsome Therapeutics, Inc. $20.0507/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056225731 CMS
AbbVie Inc. $28.8707/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999001774 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,972.14 6
PY2020 $1,035.75 8
PY2021 $1,125.14 12
PY2022 $333.84 16
PY2023 $2,352.08 118
PY2024 $1,690.51 80
PY2025 $440.19 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $51,096.00 4
PY2024 Recipient $52,520.00 2
PY2024 Principal investigator $76,277.64 20
PY2023 Principal investigator $381.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,303.52 12/31/2024 Non-covered Recipient Entity
FINGER LAKES CLINICAL RESEARCH (DBA
M21-465 Vraylar Ph3 Autism Spectrum Patients (2000-301-009) No dispute reported 06/30/2026 1100764629
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,381.00 11/15/2024 Non-covered Recipient Entity
Erg Clinical Research New York PLLC
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) No dispute reported 06/30/2026 1123477196
Recipient Eli Lilly and Company $23,429.00 11/12/2024 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137347499
Recipient Eli Lilly and Company $29,091.00 10/29/2024 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137348833
Principal investigator 1 ABBVIE INC. $150.00 10/22/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100749580
Principal investigator 1 ABBVIE INC. $1,800.00 10/03/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100745592
Principal investigator 1 ABBVIE INC. $495.45 09/04/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100740030
Principal investigator 1 ABBVIE INC. $150.00 08/22/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100737470
Principal investigator 1 ABBVIE INC. $850.43 08/02/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100733664
Principal investigator 1 Biogen, Inc. $4,137.00 07/27/2024 Non-covered Recipient Entity
Richmond Behavioral Associates
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1104840391
Principal investigator 1 ABBVIE INC. $675.00 07/18/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100730306
Principal investigator 1 ABBVIE INC. $1,500.00 07/11/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100728744
Principal investigator 1 ABBVIE INC. $1,980.00 07/11/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100728748
Principal investigator 1 ABBVIE INC. $3,573.45 07/05/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100727602
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,680.40 07/01/2024 Non-covered Recipient Entity
Erg Clinical Research New York PLLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1123477192
Principal investigator 1 ABBVIE INC. $4,250.00 06/13/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100723520
Principal investigator 1 ABBVIE INC. $3,400.15 06/06/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100722676
Principal investigator 1 ABBVIE INC. $900.00 06/03/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100720434
Principal investigator 1 ABBVIE INC. $8,999.55 06/03/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100720436
Principal investigator 1 ABBVIE INC. $23,335.18 05/09/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100717088
Principal investigator 1 ABBVIE INC. $716.51 04/04/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710844
Principal investigator 1 ABBVIE INC. $10,000.00 02/02/2024 Non-covered Recipient Entity
ERG CLINICAL RESEARCH-NEW YORK PLLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100702944